Dear Editor,Breast cancer is one of the most lethal cancers in women,with many patients still succumbing to this dis-ease[1].Accumulating evidence demonstrates that histone deacetylase inhibitors(HDACIs)are a promisin...Dear Editor,Breast cancer is one of the most lethal cancers in women,with many patients still succumbing to this dis-ease[1].Accumulating evidence demonstrates that histone deacetylase inhibitors(HDACIs)are a promising therapeu-tic intervention for breast cancer[2],and many of them have shown favorable anti-cancer activities in both pre-clinical and clinical settings[3].However,most current HDACIs only exhibit limited efficacy against solid tumors with toxic side effects and readily produce drug resistance[4].Therefore,it is necessary to develop new HDACIs with improved anti-tumor activities and decreased toxic-ities for breast cancer therapeutics and investigate their mechanism of action.展开更多
基金supported by the National Natural Science Foundation of China(No.91849209,81803016,81703360,81903539)the Natural Science Foundation of Shandong Province(No.ZR2019HB012,ZR2021MC189)the China Postdoctoral Science Foundation(No.2019M650157).
文摘Dear Editor,Breast cancer is one of the most lethal cancers in women,with many patients still succumbing to this dis-ease[1].Accumulating evidence demonstrates that histone deacetylase inhibitors(HDACIs)are a promising therapeu-tic intervention for breast cancer[2],and many of them have shown favorable anti-cancer activities in both pre-clinical and clinical settings[3].However,most current HDACIs only exhibit limited efficacy against solid tumors with toxic side effects and readily produce drug resistance[4].Therefore,it is necessary to develop new HDACIs with improved anti-tumor activities and decreased toxic-ities for breast cancer therapeutics and investigate their mechanism of action.
